Glutamatergic neurotransmission: A potential pharmacotherapeutic target for the treatment of cognitive disorders

Pratik Chakraborty, Abhijit Dey, Abilash Valsala Gopalakrishnan, Kumari Swati, Shreesh Ojha, Anand Prakash, Dhruv Kumar, Rashmi K. Ambasta, Niraj Kumar Jha, Saurabh Kumar Jha, Saikat Dewanjee

Research output: Contribution to journalReview articlepeer-review

10 Citations (Scopus)


In the mammalian brain, glutamate is regarded to be the primary excitatory neurotransmitter due to its widespread distribution and wide range of metabolic functions. Glutamate plays key roles in regulating neurogenesis, synaptogenesis, neurite outgrowth, and neuron survival in the brain. Ionotropic and metabotropic glutamate receptors, neurotransmitters, neurotensin, neurosteroids, and others co-ordinately formulate a complex glutamatergic network in the brain that maintains optimal excitatory neurotransmission. Cognitive activities are potentially synchronized by the glutamatergic activities in the brain via restoring synaptic plasticity. Dysfunctional glutamate receptors and other glutamatergic components are responsible for the aberrant glutamatergic activity in the brain that cause cognitive impairments, loss of synaptic plasticity, and neuronal damage. Thus, controlling the brain's glutamatergic transmission and modifying glutamate receptor function could be a potential therapeutic strategy for cognitive disorders. Certain drugs that regulate glutamate receptor activities have shown therapeutic promise in improving cognitive functions in preclinical and clinical studies. However, several issues regarding precise functional information of glutamatergic activity are yet to be comprehensively understood. The present article discusses the scope of developing glutamatergic systems as prospective pharmacotherapeutic targets to treat cognitive disorders. Special attention has been given to recent developments, challenges, and future prospects.

Original languageEnglish
Article number101838
JournalAgeing Research Reviews
Publication statusPublished - Mar 2023


  • Brain
  • Cognitive Disorders
  • Excitotoxicity
  • Glutamatergic signaling
  • Therapeutic interventions

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Ageing
  • Molecular Biology
  • Neurology


Dive into the research topics of 'Glutamatergic neurotransmission: A potential pharmacotherapeutic target for the treatment of cognitive disorders'. Together they form a unique fingerprint.

Cite this